Clinical characteristics of patients with AML with mutated NPM1
| . | AML-NPM1 (n = 239) . | DN (n = 74) . | Myeloid (n = 72) . | Monocytic (n = 93) . | P* . | ||
|---|---|---|---|---|---|---|---|
| DN vs myeloid . | DN vs monocytic . | Myeloid vs monocytic . | |||||
| Female sex, n (%) | 129 (54) | 49 (66) | 41 (57) | 39 (42) | NS | .03 | NS |
| Median age (range), y | 64.8 (14-89) | 67.7 (31-89) | 64.3 (22-87) | 63.4 (14-86) | .08 | .05 | NS |
| Median CBC parameters at diagnosis (range) | |||||||
| WBC count, × 109/L | 23.9 (0.7-340) | 23.3 (0.7-340) | 12.7 (0.8-309) | 29.9 (1-269) | NS | NS | NS |
| Hemoglobin, g/dL | 9.1 (4.1-16.8) | 9.2 (4.8-15.0) | 9.2 (4.5-16.8) | 8.7 (4.1-14.9) | NS | NS | NS |
| Platelet count, × 109/L | 60.0 (6-445) | 71.0 (9-243) | 53.0 (8-240) | 60.0 (6-445) | NS | NS | NS |
| PB blast, % | 42 (0-98) | 64.8 (0-98) | 40.3 (0-97) | 33.0 (0-98) | NS | .005 | .046 |
| Cytogenetics, n (%) | |||||||
| Normal† | 189 (86) | 62 (90) | 55 (85) | 72 (85) | NS | NS | NS |
| Unknown | 20 | 5 | 7 | 8 | |||
| Clinical follow-up, n (%) | 231 (97) | 68 (92) | 70 (97) | 93 (100) | |||
| Patients receiving standard induction | 172 (75) | 44 (65) | 54 (77) | 74 (80) | NS | NS | NS |
| FLT3 inhibition‡ | |||||||
| During induction/maintenance | 28 (12) | 9 (13) | 11 (16) | 8 (9) | NS | NS | NS |
| After relapse or SCT | 16 (7) | 3 (4) | 6 (9) | 7 (8) | NS | NS | NS |
| Allogeneic SCT | 92 (40) | 25 (37) | 30 (43) | 37 (40) | NS | NS | NS |
| Allogeneic SCT in first CR | 71 (31) | 23 (34) | 22 (31) | 26 (28) | NS | NS | NS |
| . | AML-NPM1 (n = 239) . | DN (n = 74) . | Myeloid (n = 72) . | Monocytic (n = 93) . | P* . | ||
|---|---|---|---|---|---|---|---|
| DN vs myeloid . | DN vs monocytic . | Myeloid vs monocytic . | |||||
| Female sex, n (%) | 129 (54) | 49 (66) | 41 (57) | 39 (42) | NS | .03 | NS |
| Median age (range), y | 64.8 (14-89) | 67.7 (31-89) | 64.3 (22-87) | 63.4 (14-86) | .08 | .05 | NS |
| Median CBC parameters at diagnosis (range) | |||||||
| WBC count, × 109/L | 23.9 (0.7-340) | 23.3 (0.7-340) | 12.7 (0.8-309) | 29.9 (1-269) | NS | NS | NS |
| Hemoglobin, g/dL | 9.1 (4.1-16.8) | 9.2 (4.8-15.0) | 9.2 (4.5-16.8) | 8.7 (4.1-14.9) | NS | NS | NS |
| Platelet count, × 109/L | 60.0 (6-445) | 71.0 (9-243) | 53.0 (8-240) | 60.0 (6-445) | NS | NS | NS |
| PB blast, % | 42 (0-98) | 64.8 (0-98) | 40.3 (0-97) | 33.0 (0-98) | NS | .005 | .046 |
| Cytogenetics, n (%) | |||||||
| Normal† | 189 (86) | 62 (90) | 55 (85) | 72 (85) | NS | NS | NS |
| Unknown | 20 | 5 | 7 | 8 | |||
| Clinical follow-up, n (%) | 231 (97) | 68 (92) | 70 (97) | 93 (100) | |||
| Patients receiving standard induction | 172 (75) | 44 (65) | 54 (77) | 74 (80) | NS | NS | NS |
| FLT3 inhibition‡ | |||||||
| During induction/maintenance | 28 (12) | 9 (13) | 11 (16) | 8 (9) | NS | NS | NS |
| After relapse or SCT | 16 (7) | 3 (4) | 6 (9) | 7 (8) | NS | NS | NS |
| Allogeneic SCT | 92 (40) | 25 (37) | 30 (43) | 37 (40) | NS | NS | NS |
| Allogeneic SCT in first CR | 71 (31) | 23 (34) | 22 (31) | 26 (28) | NS | NS | NS |
CBC, complete blood count; CR, complete remission; NS, not significant; SCT, stem cell transplantation.
P values represent values corrected for multiple comparisons.
None of the cytogenetic abnormalities identified were defining for AML with myelodysplasia-related changes or AML with a recurrent cytogenetic abnormality.
FLT3 inhibitor therapy included midostaurin, sorafenib, and gilteritinib.